Research programme: cancer therapeutics - Bioncotech Therapeutics

Drug Profile

Research programme: cancer therapeutics - Bioncotech Therapeutics

Alternative Names: BO-011; BO-110

Latest Information Update: 14 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioncotech Therapeutics
  • Class
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Autophagy stimulants; Ephrin-B2 antagonists; IFIH1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Jan 2014 Preclinical trials in Cancer in Spain (unspecified route) prior to January 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top